Research programme: NASH therapeutics - Eli Lilly/Terns Pharmaceuticals

Drug Profile

Research programme: NASH therapeutics - Eli Lilly/Terns Pharmaceuticals

Alternative Names: Non-alcoholic steatohepatitis therapeutics; SSAO inhibitors - Terns Pharmaceuticals; TERN-201; Vascular adhesion protein-1 inhibitors - Terns Pharmaceuticals

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly
  • Developer Terns Pharmaceuticals
  • Class Hepatoprotectants; Small molecules
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Non-alcoholic steatohepatitis

Most Recent Events

  • 13 Apr 2018 Terns Pharmaceuticals plans a clinical trial for Non-alcoholic steatohepatitis
  • 04 Apr 2018 Terns Pharmaceuticals in-licenses from Eli Lilly three small molecule therapeutic candidates for the potential treatment of Non-alcoholic steatohepatitis
  • 04 Apr 2018 Preclinical trials in Non-alcoholic steatohepatitis in USA, prior to April 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top